Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Lee

Showing results (581-590 of 594) with videos related to

Pageof 60
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forwardGary J Kelloff, Scott M Lippman, Andrew J Dannenberg, et al.
Cancer Cell|May 9, 2025
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interceptionBo Zhu, Pingjun Chen, Muhammad Aminu, et al.
The Lancet. Digital Health|June 2, 2023
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B Saad, Lingzhi Hong, Muhammad Aminu, et al.
Lancet (London, England)|December 14, 2025
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trialSteven J Frank, Paul M Busse, J Jack Lee, et al.
Nature|October 22, 2025
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockadeAdam J Grippin, Christiano Marconi, Sage Copling, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Cancer Discovery|April 17, 2023
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, et al.
Cancer Discovery|May 19, 2018
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung AdenocarcinomaFerdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, et al.
Pageof 60

Showing results (581-590 of 594) with videos related to

Sort By:
Pageof 60
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forwardGary J Kelloff, Scott M Lippman, Andrew J Dannenberg, et al.
Cancer Cell|May 9, 2025
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interceptionBo Zhu, Pingjun Chen, Muhammad Aminu, et al.
The Lancet. Digital Health|June 2, 2023
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B Saad, Lingzhi Hong, Muhammad Aminu, et al.
Lancet (London, England)|December 14, 2025
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trialSteven J Frank, Paul M Busse, J Jack Lee, et al.
Nature|October 22, 2025
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockadeAdam J Grippin, Christiano Marconi, Sage Copling, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Journal of Medicinal Chemistry|February 28, 2025
Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main ProteaseJamison B Tuttle, Christophe Allais, Charlotte M N Allerton, et al.
Cancer Discovery|April 17, 2023
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, et al.
Cancer Discovery|May 19, 2018
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung AdenocarcinomaFerdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, et al.
Pageof 60